Trial Profile
A Multi-Centered Randomized Phase II Study Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Carboplatin
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 16 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Mar 2025.
- 16 Feb 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Mar 2025.
- 24 Mar 2023 Planned number of patients changed from 72 to 62.